Roche To Buy 89bio For Up To $3.5 Billion
By Amit Chowdhry ● Sep 22, 2025
Roche, a leading global pharmaceutical company, has announced that it has reached an agreement to acquire 89bio, Inc., a biopharmaceutical firm listed on Nasdaq under the ticker ETNB. 89bio is known for its focus on developing treatments for liver diseases and other cardiometabolic conditions. One of its key products, pegozafermin, is a specialized drug designed to replicate a natural protein known as fibroblast growth factor 21 (FGF21). This drug is currently in the final stages of development and aims to provide treatment options for patients suffering from Metabolic Associated Steatotic Liver Disease (MASH), specifically targeting those with moderate to severe liver fibrosis, as well as patients with cirrhosis.